A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Clinical trial NCT04674956 · UNKNOWN
Trial details
- NCT number
- NCT04674956
- Sponsor
- RenJi Hospital
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-04
- Primary completion
- 2024-12-31
- Enrollment
- 401
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.